Compare PFBC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | AMPH |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1998 | 2014 |
| Metric | PFBC | AMPH |
|---|---|---|
| Price | $94.51 | $27.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $104.67 | $35.17 |
| AVG Volume (30 Days) | 69.2K | ★ 479.9K |
| Earning Date | 10-20-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.87 | 2.27 |
| Revenue | $271,347,000.00 | ★ $723,305,000.00 |
| Revenue This Year | $3.09 | $0.74 |
| Revenue Next Year | $3.60 | $5.63 |
| P/E Ratio | ★ $9.57 | $12.21 |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $71.90 | $20.39 |
| 52 Week High | $99.45 | $46.11 |
| Indicator | PFBC | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 62.39 |
| Support Level | $88.89 | $24.92 |
| Resistance Level | $96.00 | $27.83 |
| Average True Range (ATR) | 1.88 | 1.20 |
| MACD | 0.40 | 0.21 |
| Stochastic Oscillator | 77.50 | 74.94 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking which includes Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals. The bank generates a majority of its revenue from Southern and Northern California and Flushing.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.